Study to Assess the Effect of BMS-790052 on the Pharmacokinetics of Ortho Tri-Cyclen® in Healthy Female Subjects



Status:Completed
Conditions:Hepatitis
Therapuetic Areas:Immunology / Infectious Diseases
Healthy:No
Age Range:18 - 45
Updated:4/21/2016
Start Date:October 2009
End Date:February 2010

Use our guide to learn which trials are right for you!

The Effect of the Co-administration of BMS-790052 on the Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Norgestimate (Ortho Tri-Cyclen®) in Healthy Female Subjects

The purpose of this study is to assess the effect of BMS-790052 on the pharmacokinetics of
Ortho Tri-Cyclen® in healthy female subjects.


Key Inclusion Criteria:

- Healthy female subjects, 18-45 years, BMI 18-32 kg/m².

- Must be using an adequate method of contraception to avoid pregnancy throughout the
study.

Key Exclusion Criteria:

- Abnormal Pap smear within 1 yr of dosing, and abnormal menstrual cycle during the 3
months prior to enrollment.

- Any significant or chronic uncontrolled medical illness.
We found this trial at
3
sites
St. Laurent, Quebec
1445
mi
from
St. Laurent,
Click here to add this to my saved trials
Austin, Texas 78752
512
mi
from
Austin, TX
Click here to add this to my saved trials
Tempe, Arizona 85283
845
mi
from
Tempe, AZ
Click here to add this to my saved trials